9th January 2018, California, United States of America – Aravax, an Australian biotechnology company revolutionising peanut allergy treatment, today held the first meeting of its newly appointed Scientific Advisory Board, at the Gordon’s Research Conference on Food Allergy at Ventura Beach in California.
Aravax is delighted to welcome 5 members to the Scientific Advisory Board.
Mark Larché, PhD, is Professor of Medicine at McMaster University, Canada. He is also Chair in Lung Immunology at St. Joseph’s Healthcare, and the Canada Research Chair in Allergy & Immune Tolerance. Professor Larché brings world leading expertise in translational medicine and the development of peptide-based vaccines for chronic immunological diseases including allergy.
Wesley Burks, M.D, FAAAAI, is the Curnen Distinguished Professor of Pediatrics at the University of North Carolina (UNC) School of Medicine, United States of America. He is also Executive Dean for the School of Medicine at the UNC and Executive Director of the UNC Food Allergy Initiative. Professor Burks brings over 30 years of experience undertaking and leading clinical food allergy research, including clinical presentations of food allergy, immunotherapy for food allergy and the properties of food contributing to allergenicity.
Katrina (Katie) Allen, MBBS, BMedSc., FRACP, PhD, FAAAAI, FAHMS, is Professor of Pediatric Food Allergy at the Murdoch Children’s Research Institute, Royal Children’s Hospital Melbourne, Australia. She is also Theme Director of Population Health and Director of the Australian Centre of Food and Allergy Research. Professor Allen brings extensive experience in translating research findings into clinical practice and public health policy to ensure the best outcomes for children with food allergy.
Gideon Lack, MA, MBBCH, FRCP CH, MD, is Professor of Paediatric Allergy at King’s College London, U.K. He is also Head of the Clinical Academic Paediatric Allergy Service, Guy’s and St Thomas’ NHS Foundation Trust. Professor Lack brings over 20 years’ experience of research into severe childhood asthma, peanut allergy and new strategies to prevent and treat food allergies, eczema, asthma, and hay fever in children and adults.
Kari C. Nadeau, MD, PhD, is Professor of Pediatric Food Allergy at the Stanford School of Medicine, United States of America. She is also Director of the Sean N. Parker Centre for Allergy and Asthma Research, a Section Chief of Allergy and Asthma at the Stanford School of Medicine, and an endowed Professor under the Naddisy Family Foundation. Professor Nadeau brings commercial, clinical and research expertise in understanding the factors responsible for the increased prevalence of allergies and asthma, improving diagnostics, developing new treatments and understanding the immunological mechanisms underlying these diseases.
Pascal Hickey, CEO of Aravax, said “we are extremely pleased to have attracted such a distinguished panel of researchers to Aravax’s Scientific Advisory Board. We look forward to working closely with the Board members as we develop plans for phase 2 studies of PVX108 novel immunotherapy for the treatment of peanut allergy.”